Research article

Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy

Elisabetta Munzone¹, Giuseppe Curigliano¹, Andrea Rocca¹, Giuseppina Bonizzi², Giuseppe Renne³, Aron Goldhirsch¹ and Franco Nolè¹

¹Department of Medicine, Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
²Department of Experimental Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
³Division of Pathology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy

Corresponding author: Elisabetta Munzone, elisabetta.munzone@ieo.it

Received: 8 Mar 2005  Revisions requested: 5 May 2005  Revisions received: 12 Sep 2005  Accepted: 11 Nov 2005  Published: 7 Dec 2005

Breast Cancer Research 2006, 8:R4 (doi:10.1186/bcr1366)
This article is online at: http://breast-cancer-research.com/content/8/1/R4
© 2005 Munzone et al.; licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction The amounts of estrogen receptor (ER) and progesterone receptor (PgR) in a primary tumor are predictive of the response to endocrine therapies of breast cancer. Several patients with ER-positive primary tumors relapse after adjuvant endocrine therapy with no ER expression in the recurrent tissue; much fewer with a recurrent disease after an ER-negative primary tumor may become endocrine responsive. These sequences of events indicate that a phenotype based on ER expression may not be a permanent feature of breast cancer.

Methods Ten patients with advanced breast cancer whose tumors overexpressed HER-2, but not ER or PgR, were treated with weekly trastuzumab at standard doses with or without chemotherapy.

Results Three out of 10 patients showed overexpression of ERs first appearing after 9, 12 and 37 weeks, respectively, from the initiation of trastuzumab. Two of these patients were subsequently treated with endocrine therapy alone: one of them received letrozole for 3 years without evidence of progression.

Conclusion Therapeutic targets enabling the appearance of an endocrine responsive disease may increase treatment options for patients with breast cancer. Furthermore, these clinical data suggest that an ER-negative phenotype is a multi-step process with a reversible repression modality, and that some ER-negative tumors may either revert to an ER-positive phenotype, allowing an endocrine treatment to be effective.

Introduction

Biological features of endocrine responsiveness, namely the overexpression of estrogen receptor (ER) and/or progesterone receptor (PgR), are important predictive and prognostic markers in breast cancers [1]. About 50% of patients with ER-positive primary tumors that relapse after adjuvant tamoxifen therapy have recurrent tumors in which ER expression is lost [2]. Progression to an ER-negative phenotype typically involves the constitutive overexpression of growth-promoting genes that are normally regulated by estrogens, thereby leading to a loss of estrogen dependence, resistance to anti-estrogens, and a more aggressive phenotype overall.

The re-expression of ER in tumors in which ER has been lost or is not expressed could therefore indicate sensitivity to endocrine therapy. ER-negative tumors frequently overexpress growth factor receptors such as epidermal growth factor receptor (EGFR) or c-erbB2 [3,4], as do many ER-negative breast cancer cell lines, suggesting that upregulated growth factor signaling might provide an alternative growth stimulus. The overexpression of EGFR and c-erbB2 is also an important prognostic indicator of breast cancer, independently of their inverse correlation with ER expression [5,6]. This increased expression and/or activation of growth factor receptors correlates with increased mitogen-activated protein kinase (MAPK) activity, both in tumors and in cell lines [7-9]. Using cell lines...
that overexpress constitutively active forms of Raf-1, MAPK/ERK kinase (MEK)-1, or c-erbB-2 and ligand-activatable EGFR, some authors have shown that the resultant hyperactivation of MAPK (ERK1/2) activity through these signaling pathways leads to the downregulation of ERα. This downregulation is not a consequence of ligand-independent ERα activation and is reversible in vitro. Abrogation of ERK (extracellular signal-regulated kinase) activity with the use of either pharmacologic inhibitors or dominant-negative ERK constructs reverses the downregulation of ERα and restores its activity [10]. These data suggest that upregulated growth factor signaling via MAPK is directly linked to the loss of ER expression and generation of the ER-negative phenotype and that, at some stage in the progression pathway, the ER-negative phenotype may be not permanent.

As a consequence, therapeutic targets enabling the restoration of ER expression may provide beneficial treatment strategies for breast cancer patients.

Both gefitinib (Iressa®), which inhibits the kinase activity of EGFR, and trastuzumab (Herceptin™), a monoclonal antibody against c-erbB2, have been shown to reduce MAPK activity [11].

These data support the hypothesis that a patient with advanced breast cancer with ER-negative tumors and c-erbB2 overexpressed could revert from an ER-negative phenotype to ER-positive after treatment with trastuzumab.

### Methods

From August 1999 to November 2002, 10 patients with advanced breast cancer whose tumors overexpressed HER-2 (defined as a HercepTest score of 3+; Dako, Carpinteria, CA, USA), and with both ER and PgR negative were treated with weekly trastuzumab (Hercept in; Hoffman La-Roche, Basel, Switzerland) at a weekly dosage of 2 mg/kg intravenously (after an initial loading dose of 4 mg/kg) plus chemotherapy. Paclitaxel (Taxol®; Bristol-Myers Squibb Company, Princeton, NJ, USA) at a weekly dosage of 90 mg/m² intravenously, for three consecutive weeks every 4 weeks, was given to nine patients; the tenth patient received vinorelbine (Navelbine®; Pierre Fabre Pharma-30, Pierre Fabre Medicament-F-2849) at a weekly dosage of 20 mg/m² per week intravenously, for three consecutive weeks every 4 weeks.

Chemotherapy started concomitantly with trastuzumab in seven patients and, after evidence of progression, to trastuzumab alone in three patients. Tumor tissue for immunohistochemical analysis was obtained from all patients at baseline and after a median period of 9 weeks (range 3 to 37 weeks) of treatment with trastuzumab, with or without chemotherapy. All samples were processed and read in the same laboratory.

Basal evaluations were assessed on primary tumors in four patients and on metastatic sites in six (skin in four patients, pleura in one, liver in one). Tumor immunohistochemical reassessment was performed on the primary tumor in one patient, on the metastatic skin tissue in seven and on other metastatic sites.

### Table 1

| Patient | Baseline evaluation | After treatment | Time A | Time B | Second assessment | HT | Clinical response |
|---------|---------------------|----------------|--------|--------|-------------------|----|-------------------|
|         | ER, % | PgR, % | HER2, % (score) | First | Chemotherapy | ] |          |          |
| 1       | 0     | 0     | 80 (3+) | Skin  | Paclitaxel | 20 | Skin  | 10 | 70 (3+) | No PR |
| 2       | 0     | 0     | 70 (3+) | Pleura | Paclitaxel | 87 | Pleura | 0  | 75 (3+) | No SD |
| 3       | 0     | 0     | 90 (3+) | Skin  | None° | 4  | Skin  | 0  | 90 (3+) | No PR |
| 4       | 0     | 0     | 40 (3+) | Skin  | Paclitaxel | 31 | Skin  | 0  | 90 (3+) | No PD |
| 5       | 0     | 0     | 90 (3+) | Liver | None° | 12 | Ovary | 50 | 80 (3+) | Yes PD |
| 6       | 0     | 0     | 95 (3+) | Breast | Paclitaxel | 2  | Breast | 20 | 90 (3+) | Yes PR |
| 7       | 0     | 0     | 80 (3+) | Skin  | None° | 64 | Skin  | 0  | 95 (3+) | No PR |
| 8       | 0     | 0     | 90 (3+) | Lung  | Paclitaxel | 2  | Skin  | 0  | 90 (3+) | No SD |
| 9       | 0     | 0     | 80 (3+) | Skin  | Paclitaxel | 51 | Skin  | 0  | 40 (2+) | No PR |
| 10      | 0     | 0     | 90 (3+) | Skin  | Vinorelbine | 17 | Skin  | 0  | 90 (3+) | No PR |

| First | Time A | Chemotherapy | Time B | Second | ER, % | PgR, % | HER2, % (score) | HT | Clinical response |
|---|--------|--------------|--------|--------|-------|--------|-----------------|----|-------------------|
| 20 | 9 | Skin | 10 | 70 (3+) | No PR |
| 87 | 11 | Pleura | 0  | 75 (3+) | No SD |
| 4 | 9 | Skin | 0  | 90 (3+) | No PR |
| 31 | 9 | Paclitaxel | 0  | 90 (3+) | No PD |
| 5 | 12 | Ovary | 50 | 80 (3+) | Yes PD |
| 37 | Breast | 20 | 90 (3+) | Yes PR |
| 64 | 4 | Skin | 0  | 95 (3+) | No PR |
| 4 | 4 | Paclitaxel | 0  | 90 (3+) | No SD |
| 51 | 22 | Skin | 0  | 40 (2+) | No PR |
| 17 | 3 | Vinorelbine | 0  | 90 (3+) | No PR |

The table shows the evaluation of patients’ characteristics at baseline with the site of disease at which the biological characteristics were evaluated, and after treatment with trastuzumab with the site of disease at which the biological characteristics were reassessed. ER, estrogen receptor; first assessment, site of disease where ER, PgR and HER2 were evaluated at baseline; HT, hormonal treatment; PgR, progesterone receptor; second assessment, site of disease where ER, PgR and HER2 were reassessed; time A, time elapsed between first assessment and treatment start (weeks); time B, time elapsed between trastuzumab start and second assessment (weeks). PD, progressive disease. SD, stable disease. PR, partial response.

°Paclitaxel was introduced after progression to trastuzumab alone.
sites in the remaining two (pleura in one, ovary in one) (Table 1).

Response to treatment was assessed in accordance with World Health Organization criteria.

The study protocol was reviewed and approved by the research ethics committee of the study center and relevant regulatory authorities. The study treatment was performed in accordance with Good Clinical Practice and the Helsinki declaration. Written informed consent was obtained from all patients.

Results
We observed that 3 out of 10 patients had tumors that were ER positive (at least 10% of cells) after the histologic reassessment (see Table 1).

Patient 1 had a metastatic disease to bone, skin and liver and had a partial response to trastuzumab and paclitaxel after 1 month. Two months after treatment start she had a skin biopsy in the same site as baseline, with evidence of ER positivity (10%). The response to the combination chemotherapy and immunotherapy was maintained for 5 months. The patient was subsequently treated with multiple cycles of chemotherapy and died of progressive disease about 1 year later.

Patient 5 had metastatic disease to the liver and did not respond to trastuzumab. After 2 months from the start of trastuzumab treatment she underwent ovariectomy because of progressive disease. The ER and PgR assessment on ovarian metastases was positive (ER 50%; PgR 40%). Subsequently she received trastuzumab and paclitaxel without any response, and afterwards letrozole for 3 months with a progression to CNS (central nervous system). The patient died 6 months later.

Patient 6 underwent therapy with paclitaxel and trastuzumab for a cutaneous and controlateral relapse and had a partial response after 1 month of treatment. Seven months later she underwent mastectomy with evidence of positive ER. Subsequently the patient received letrozole for 3 years without progression to disease. Recently, she had a subcutaneous relapse that was biopsied and showed negative for ER and PgR, with HER-2 overexpressed; she is currently being treated with vinorelbine and trastuzumab.

In these three patients we observed the reversion of ER to a positive phenotype after 9, 12 and 37 weeks, respectively, from the start of treatment with trastuzumab. In two patients (patients 1 and 6) trastuzumab was given concomitantly with paclitaxel; the third (patient 5) had received trastuzumab alone when ER re-expression was assessed.

Discussion
This is the first report of an ER-negative phenotype changing to ER positive after a trastuzumab-containing therapy in patients with advanced breast cancer. Interestingly, previous reports evaluating the use of trastuzumab in the preoperative setting in patients with locally advanced breast cancer do not address this particular issue [12,13].

The patient sample was limited, but this could be an important anecdotal and hypothesis-generating report that should be confirmed in larger trials.

Another potential limit was that the reassessment was performed at a variable time point after the start of therapy, and the timing was not predefined. Our three patients had a reversion of ER to a positive phenotype after 9, 12 and 37 weeks from the start of treatment with trastuzumab. For this reason we do not have data on which to base a hypothesis about the optimal timing for performing the reassessment.

A recent report by Arpino et al. proposed that a lack of PgR expression could be a reflection of active signaling in the HER family and, as a consequence, the response to trastuzumab might be different in the PgR-positive and PgR-negative subsets [14]. Interestingly, two of our patients after ER reversion to a positive phenotype remained PgR negative; both had a partial response to trastuzumab, whereas the only patient who also had a PgR reversion was resistant to trastuzumab.

Other studies that address ER loss reversibility in breast cancer cell lines involve treatments with demethylating agents such as 5-azacytidine [15,16]. About 25% of ER-negative breast tumors were found to contain methylated ER [17]. However, several ER-positive tumors also showed similar degrees of methylation [18]. Methylation, by modifying the DNA structure assisting in the recruitment of histone deacetylases, ensures that the gene is in an inactive conformation. If methylation occurs as a step subsequent to another mechanism of ER repression, one would predict that some ER-negative breast tumors at an earlier point in a progression pathway do not express ER because one of these other mechanisms is still operative. In such tumors, it might then be possible to reverse this phenotype and restore antiestrogen sensitivity, perhaps by using a demethylating agent.

An interesting recently reported transcription factor that might be linked to hormone-independent breast cancer, as well as elevated growth factor signaling, is NF-κB. Its activity is elevated in hormone-independent breast cancer, and it is implicated in enhanced cell survival and chemoresistance in cancer [19]. Holloway et al. have shown recently that an elevation in NF-κB activity is attributable to enhanced growth factor signaling through ERK1/2; inhibiting this NF-κB activity, either pharmacologically or through the expression of a constitutively active IκB, partly restores ER activity and expression in these
cells. These findings suggest a role for cytoplasmic substrates of MAPK in ER downregulation in breast cancer and further support a role for MAPK-induced NF-κB activity in this down-regulation [20].

**Conclusion**

We conclude that our clinical data – although limited in the patient sample – support previous assessments in vitro, suggesting that an ER-negative phenotype may be a multi-step process with a reversible repression modality, and that some ER-negative tumors might revert to the ER-positive phenotype allowing an endocrine-based treatment.

Although further studies are essential to show that inhibitors of mitogenic signaling can restore ER expression and/or function in breast tumors, coupling molecules such as signal transduction inhibitors, monoclonal antibodies, demethylating agents or NF-κB inhibitors with antiestrogens could result in therapies that are better tolerated and active for the treatment of ER-negative breast cancer. In addition, once the MAPK substrate or substrates responsible for ER downregulation are identified, they could provide an additional drug target.

**Competing Interests**

The authors declare they have no competing interests.

**Authors’ contributions**

EM made substantial contributions to the conception and design of the study, the acquisition of data and the analysis and interpretation of data, and drafted the manuscript. GC made substantial contributions to the conception and design of the study, the acquisition of data and the analysis and interpretation of data, and contributed to drafting the manuscript. AR made substantial contributions to the conception and design of the study and contributed to drafting the manuscript. GB made substantial contributions to the conception and design of the study and to the analysis and interpretation of data. GR processed and read all histological samples and performed the immunohistochemistry. AG made substantial contributions to the conception and design of the study and gave the final approval of the version to be published. FN made substantial contributions to the conception and design of the study, the acquisition of data and the analysis and interpretation of data. All authors read and approved the final manuscript.

**References**

1. Early Breast Cancer Trialists’ Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. *Lancet* 1998, 351:1451-1467.
2. Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR, Dowsett M: Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. *Cancer Res* 1995, 55:3331-3338.
3. Sainsbury JR, Fardoun JF, Cherubini L, Harris A, Cleary D, Paul D, Peckham S: Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. *Lancet* 1985, 1:136-136.
4. Quenell N, Wallis J, Bonichon F, de Mascarel I, Torni I, Durand M, Avril A, Coinde JM: The prognostic value of c-erbB2 in primary breast carcinomas: a study of 942 cases. *Breast Cancer Res Treat* 1995, 38:283-291.
5. Seshadri R, Fargara P, Horsfall DJ, McCaul K, Setlur V, Kitchen P: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. *J Clin Oncol* 1993, 11:1936-1942.
6. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, et al.: HER-2/neu gene amplification characterised by fluorescence in situ hybridisation: poor prognosis in node-negative breast carcinomas. *J Clin Oncol* 1997, 15:2894-2904.
7. Goe JM, Robertson JF, Ellis IO, Nicholson RI: Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. *Int J Cancer* 2001, 95:247-254.
8. Hermanto U, Zong CS, Wang LH: Inhibition of mitogen-activated protein kinase in human breast cancer cells displaying enhanced insulin-like growth factor I-mediated mitogen-activated protein kinase activation. *Cell Growth Differ* 2000, 11:855-664.
9. Oh AS, Lorant LH, Holloway JN, Miller DL, Kem FG, El-Ashry D: Hyperactivation of MAPK induces loss of ER expression in breast cancer cells. *Mol Endocrinol* 2001, 15:1344-1359.
10. Normanno N, Campiglio M, De La Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S: Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. *Ann Oncol* 2002, 13:65-72.
11. Burstein HJ, Harris LN, Gelman R, Lyster SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter J, Gadd MA, et al.: Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide/HER2 overexpressing stage II or III breast cancer: a pilot study. *J Clin Oncol* 2003, 21:46-53.
12. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magliocchi C, Gibelli N, et al.: Study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. *Clin Cancer Res* 2004, 10:5650-5655.
13. Arpino G, Weiss H, Lee AV, Schirf R, De Placido S, Osborne CK, Ellridge RM: Estrogen receptor-negative, progesterone receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. *J Natl Cancer Inst* 2005, 97:1254-1261.
14. Ottaviano YL, Issa JP, Parf FF, Smith HS, Baylin SB, Davidson NE: Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. *Cancer Res* 1994, 54:2552-2555.
15. Ferguson AT, Lapidos RG, Baylin SB, Davidson NE: Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. *Cancer Res* 1995, 55:2279-2283.
16. Lapidos RG, Ferguson AT, Ottaviano YL, Parf FF, Smith HS, Weitzman SA, Baylin SB, Issa J-P, Davidson NE: Methylation of estrogen and progesterone receptor genes 5′ CpG islands correlates with ER and PgR gene expression in breast tumors. *Clin Cancer Res* 1996, 2:805-810.
17. Lapidos RG, Nass SJ, Butash KA, Parf FF, Weitzman SA, Graff JG, Herman JG, Davidson NE: Mapping of ER gene CpG island methylation-specific polymerase chain reaction. *Cancer Res* 1998, 58:2518-2519.
18. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet R Jr, Sledge GW Jr: Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. *Mol Cell Biol* 1997, 17:3629-3639.
19. Holloway JN, Murthy S, El-Ashry D: A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-alpha down-regulation in breast cancer cells: the role of nuclear factor-κB. *Mol Endocrinol* 2004, 18:1396-1410.